Zydus and Lupin Ink Agreement for Co-Marketing Semaglutide Weight-Loss Injection in India

Licensing and Supply Agreement Between Zydus Lifesciences and Lupin Expands Access to Semaglutide Therapy in India

Key Highlights

• Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co-market a semaglutide injection in India.
• The agreement aims to expand access to advanced therapies for diabetes and weight management.

Agreement Details

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

As part of the deal, Zydus Lifesciences will supply the semaglutide injection, while both companies will sell it under separate brand names. Lupin will have semi-exclusive rights to market Zydus' semaglutide (15 mg/3 ml) delivered through a reusable pen device. Lupin will commercialize the drug under the brands Semanext and Livarise, while Zydus will market it as SemaGlyn, Mashema, and Alterme.

Financial Arrangements

Lupin will pay Zydus licensing fees along with milestone-based payments. The agreement positions both companies to strengthen their presence in the fast-expanding treatment segment for GLP-1 therapies.

Market Opportunity

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

Semaglutide is approved as an adjunct to diet and exercise for adults with type 2 diabetes who have insufficient glycemic control or cannot take metformin. It is also indicated for chronic weight management in adults with obesity and related comorbidities. With rising demand for GLP-1 therapies globally, the co-marketing arrangement is expected to benefit both companies in a growing treatment segment.